Wedbush analyst Liana Moussatos reiterated a Buy rating on Aquestive Therapeutics (AQST – Research Report) today and set a price target of $28.00. The company’s shares closed last Monday at $4.68.
According to TipRanks.com, Moussatos is a 2-star analyst with an average return of 1.4% and a 35.3% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Eiger Biopharmaceuticals, and BioMarin Pharmaceutical.
Currently, the analyst consensus on Aquestive Therapeutics is a Strong Buy with an average price target of $15.40, representing a 254.8% upside. In a report released today, JMP Securities also reiterated a Buy rating on the stock with a $15.00 price target.
See today’s best-performing stocks on TipRanks >>
Based on Aquestive Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $15.35 million and GAAP net loss of $12.37 million. In comparison, last year the company earned revenue of $21.68 million and had a GAAP net loss of $2.33 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aquestive Therapeutics, Inc. is a specialty pharmaceutical company focused on identifying, developing, and commercializing differentiated products to address unmet medical needs. The company has a late-stage proprietary product pipeline focused on the treatment of Central nervous system (CNS) diseases, as well as orally-administered complex molecules that can be alternatives to invasively-administered standard of care therapies. Its product candidates include Libervant, Sympazan, and AQST-117 (Riluzole). Aquestive Therapeutics develops and delivers drugs via its PharmFilm® technology. The firm also collaborates with pharmaceutical partners to bring new molecules to market in differentiated and highly-marketable dosage forms. In addition to its proprietary product candidates, the company, with its partners, has a portfolio of development-stage products and commercialized products, such as Suboxone, a prescription medicine for the treatment of opioid dependence. The company was founded in January 2004 and is headquartered in Warren, NJ.
Read More on AQST:
